Blueprint Medicines Reports Positive Test Results For Rare Disease Treatment; BPMC Stock Jumps

Blueprint Medicines Reports Positive Test Results For Rare Disease Treatment; BPMC Stock Jumps

Blueprint Medicines on Tuesday reported positive test results for its treatment for a potentially fatal rare disease, sending BPMC stock to a 13-month high extending beyond a buy zone.